Microgen PLC
3 December 2001
Tax benefit of £1.5 million
The Group's main trading subsidiary, Microgen UK Limited, has received
confirmation from the Inland Revenue of settlement of its Corporation Tax
liability for the period ended 31 December 1998. The settlement will result in a
prior years' Corporation Tax credit of approximately £1.5 million being
recognised in the Group profit and loss account for the period ending 31
December 2001 equating to earnings per share of approximately 2.9 pence. A cash
repayment of £1.4 million including interest has been received from the Inland
Revenue.
The principal issues that gave rise to the repayment are:
(i) the agreement with the Inland Revenue of March 1982 valuations of shares in
Microgen UK Limited's overseas subsidiaries, Capella AB and Eurocom Depora,
disposed of in October 1998 in the first phase of the strategic restructuring of
the Group; and,
(ii) a provision for obligations under surplus property leases made in 1998 that
is now an allowable deduction for tax purposes.
There are consequent amendments to Microgen UK Limited's Corporation Tax
computations for 1999 and 2000 relating to movements on the surplus property
provision and these amendments are incorporated into the prior years' tax credit
of £1.5 million stated above
Contact :
Mike Phillips, Group Finance Director 01753-847123
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.